Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents

被引:59
作者
Pieroni, Marco [1 ]
Wan, Baojie [2 ]
Cho, Sanghyun [2 ]
Franzblau, Scott G. [2 ]
Costantino, Gabriele [1 ]
机构
[1] Univ Parma, Dipartimento Farm, I-43124 Parma, Italy
[2] Univ Illinois, Coll Pharm, Inst TB Res, Chicago, IL 60612 USA
关键词
Tuberculosis; Medicinal chemistry; Resistance; Drug discovery; 2-Aminothiazoles; NONREPLICATING MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANT TUBERCULOSIS; BIOLOGICAL EVALUATION; GROWTH-INHIBITORS; POTENT; ESTERS; SERIES; ASSAY;
D O I
10.1016/j.ejmech.2013.11.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tuberculosis (TB) is one of the deadliest infectious diseases of all times, and its recent resurgence is a supreme matter of concern. Co-infection with HIV and, in particular, the continuous isolation of new resistant strains, makes the discovery of novel anti-TB agents a strategic priority. The research of novel agents should be driven by the accessibility of the synthetic procedure and, in particular, by the lack of cross-resistance with the drugs already marketed. Moreover, in order to shorten the duration of the therapy, and therefore decrease the rate of resistance, these molecules should be active also against the nonreplicating persistent form (NRP-TB) of the infection. The availability of an in-house small library of compounds prompted us to investigate their anti-TB activity. Two compounds, embodying a 2-aminothiazole scaffold, were found to possess a certain inhibitory activity toward Mycobacterium tuberculosis H(37)Rv, and therefore a medicinal chemistry campaign was initiated in order to increase the activity of the hit compounds and, especially, construct a plausible body of structure activity relationships. The potency of the hit compound was successfully improved, and, much more importantly, some of the molecules synthesized were found to be active toward the persistent phenotype, and, also, toward a panel of resistant strains. These findings encourage further investigations around this interesting antitubercular chemotype. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 42 条
  • [1] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
    Andries, K
    Verhasselt, P
    Guillemont, J
    Göhlmann, HWH
    Neefs, JM
    Winkler, H
    Van Gestel, J
    Timmerman, P
    Zhu, M
    Lee, E
    Williams, P
    de Chaffoy, D
    Huitric, E
    Hoffner, S
    Cambau, E
    Truffot-Pernot, C
    Lounis, N
    Jarlier, V
    [J]. SCIENCE, 2005, 307 (5707) : 223 - 227
  • [2] [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
  • [3] [Anonymous], 2013, TUBERCULOSIS
  • [4] [Anonymous], 2020, GLOB TUB REP
  • [5] Foreword from the co-editor-in-chief
    Brennan, PJ
    [J]. TUBERCULOSIS, 2001, 81 (1-2) : 1 - 1
  • [6] Antituberculosis Drug Research: A Critical Overview
    Beena
    Rawat, Diwan S.
    [J]. MEDICINAL RESEARCH REVIEWS, 2013, 33 (04) : 693 - 764
  • [7] Mycobacterial persistence: adaptation to a changing environment
    Bentrup, KHZ
    Russell, DG
    [J]. TRENDS IN MICROBIOLOGY, 2001, 9 (12) : 597 - 605
  • [8] Bhusari K.P., 2008, Asian J. Res. Chem, V1, P53
  • [9] Tuberculosis - Metabolism and respiration in the absence of growth
    Boshoff, HIM
    Barry, CE
    [J]. NATURE REVIEWS MICROBIOLOGY, 2005, 3 (01) : 70 - 80
  • [10] Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis
    Cho, Sang Hyun
    Warit, Saradee
    Wan, Baojie
    Hwang, Chang Hwa
    Pauli, Guido F.
    Franzblau, Scott G.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) : 1380 - 1385